Research programme: antibacterials - FAB Pharma

Drug Profile

Research programme: antibacterials - FAB Pharma

Alternative Names: MUT 11931; MUT-37307

Latest Information Update: 03 Oct 2012

Price : $50

At a glance

  • Originator Mutabilis
  • Developer FAB Pharma; Mutabilis
  • Class Phenols; Small molecules
  • Mechanism of Action Enoyl-ACP reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Preclinical Methicillin-resistant Staphylococcus aureus infections; Staphylococcal infections

Most Recent Events

  • 31 Oct 2011 Preclinical development is ongoing in France
  • 28 Oct 2008 Antimicrobial data from in vitro studies and pharmacodynamics and adverse events data from preclinical studies in Bacterial infections presented at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy and 46th Annual Meeting of the Infectious Diseases Society of America (ICAAC/IDSA-2008)
  • 28 Oct 2008 Antimicrobial data from two in vitro studies presented at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy and 46th Annual Meeting of the Infectious Diseases Society of America (ICAAC/IDSA-2008) ,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top